Patents by Inventor Robert M. Chanock

Robert M. Chanock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4552757
    Abstract: A method of producing a vaccine useful in animals which comprises producing a reassortment by gene exchange from an avian influenza A virus parent and an animal influenza A virus parent and then selecting for the reassortant containing two animal surface antigen genes and six avian internal genes by temperature and antibodies.
    Type: Grant
    Filed: December 20, 1983
    Date of Patent: November 12, 1985
    Assignee: St. Jude Children's Research Hospital
    Inventors: Brian R. Murphy, Robert M. Chanock, Robert G. Webster, Virginia S. Hinshaw
  • Patent number: 4341870
    Abstract: This invention relates to a precursor or intermediate for a rotavirus vaccine to protect infants and young children against diarrhea caused by rotavirus. The invention is the efficient propagation of a strain of human rotavirus type 2 prepared by a method of cultivation by multiple passages in vivo in gnotobiotic piglets and by multiple passages in vitro subsequently in AGMK (African green monkey kidney) cell cultures. Additionally, rotavirus is treated with a biologically active amount of trypsin prior to growth in AGMK cells, and the inoculated cell cultures are centrifuged at a low centrifugal force before incubation.
    Type: Grant
    Filed: November 19, 1980
    Date of Patent: July 27, 1982
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Richard G. Wyatt, Walter D. James, Edward H. Bohl, Kenneth W. Theil, Linda J. Saif, Anthony R. Kalica, Harry B. Greenberg, Albert Z. Kapikian, Robert M. Chanock
  • Patent number: 3992522
    Abstract: A method and resulting temperature sensitive (ts) recombinants which may be produced by modifying wild-type influenza A viruses by utilization of chemically mutagenized donor viruses possessing ts lesions and shut off temperatures in the area 37.degree.-38.degree. C. Such a recombinant virus has been produced that contains the surface H3 antigen of influenza A/Hong Kong/1968 (H3N2) virus and a temperature-sensitive (ts) lesion derived from a ts mutant of influenza A/Great Lakes/1965 (H2N2) virus. Additional donor viruses include influenza A/Hong Kong/1968-ts-1[A], influenza A double recombinant 10B, and influenza A/Hong Kong/1968-ts-1[E]. When utilized as a vaccine, these temperature-sensitive recombinant viruses have the facility to develop only mild symptoms, but the infection induces complete resistant to influenzal disease produced by challenge with a virulent wild-type virus. The temperature-sensitive donor mutant is prepared chemically by growth of the virus in the presence of 5-fluorouracil (5-FU).
    Type: Grant
    Filed: June 18, 1975
    Date of Patent: November 16, 1976
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventors: Robert M. Chanock, Brian R. Murphy